Compare S&P Global Inc (SPGI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs Tango Therapeutics Inc. — how do they compare? S&P Global Inc trades at $411.5 (market cap $120.87B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: S&P Global Inc is far larger — about 32.2× Tango Therapeutics Inc.'s market cap, and S&P Global Inc pays a 0.95% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold S&P Global Inc for 124 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPGI | TNGX | |
|---|---|---|
Market Cap | $120.87B | $3.75B |
Volume | 1,391,754 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $517.92 | $32.90 |
52-Week Low | $370.42 | $7.50 |
Typical Hold Time | 124 Days | 0 Days |
Enterprise Value | $132.35B | $2.77B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPGI trades at $409.99, down 0.53% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong revenue growth to $15.34 billion in 2025, with net income reaching $4.47 billion and a robust net margin of 30.54%. Recent developments include the acquisition of OpenZeppelin and the launch of new risk assessment services, expanding its market intelligence offerings.
The outlook remains positive with analyst consensus strongly bullish, an average price target of $509.50 implying significant upside. Risks include high valuation multiples and exposure to economic cycles, but sustained profitability and strategic expansions support long-term growth potential for investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
